Navigation Links
A Recent Study by ITG's Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- A study published this week by ITG's Majestic Market Research revealed that Novartis' recently approved drug, Gilenya, continues to steal share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year.  Gilenya came onto the market in late September 2010 as the first FDA-approved oral disease-modifying MS drug.  Despite negative sentiment around Gilenya's lengthy initiation process, neurologists are embracing the new drug at an impressive rate.  Real time data from ITG's proprietary physician panel indicate that Gilenya was the disease-modifying treatment of choice for 20% of new written MS prescriptions in April.  Furthermore, surveyed neurologists indicated that their prescribing of Gilenya will increase significantly over the course of 2011 as they continue to shift inadequate responders from other MS therapies to the new drug.

The study takes an in-depth look at how Gilenya's multi-step initiation process is impacting neurologists' use of the drug.  According to neurologists, new treatment starts for Gilenya typically take between three to six weeks and involve the scheduling and organization of prescreening tests and ongoing monitoring for adverse events.  

Physicians reported that Novartis plays an important role in facilitating these steps. In fact, 63% of Gilenya prescribers indicated that they receive support from Novartis during this process, and 25% of them classified this assistance as superior to what competing companies offer for their products.  

By comparison, neurologists appear unable to get over similar concerns about Acorda Therapeutics' Ampyra, which was launched in March 2010 as the first FDA approved drug to improve walking in MS patients. Like Gilenya, Ampyra is associated with an onerous initi
'/>"/>

SOURCE ITG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
2. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
3. Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
4. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
5. Recent Studies Suggest Popular Diet Pill Relacore Reduces Acne Breakouts
6. Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing
7. Recent Data Study Suggests Cortisol Could Help Alleviate Suffering for Those With Chronic Fatigue Syndrome and Fibromyalgia
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
10. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
11. Presentations From Recent Heart Rhythm Society Meeting Validate the Safety and Efficacy of Ablation Frontiers Technology in 230 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Vanda ... today announced top-line results of the Phase II ... and efficacy of tradipitant as a monotherapy in ... atopic dermatitis. Despite a highly significant and clinically ... from baseline, p<0.0001) as measured on a 100mm ...
(Date:3/4/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... regenerative medicine, today announced that Pedro Lichtinger , ... Bell ® of the New York Stock Exchange ... as an NYSE MKT listed company on October 8, ... a trusted partner to Asterias Biotherapeutics, and we are ...
(Date:3/4/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the U.S. healthcare industry, today announced that it ... results on Monday, March 9, 2015 after the market ... conference call for investors on Monday, March 9, 2015 ... and full year 2014 performance and results.  To participate ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 2Asterias Biotherapeutics to Ring Opening Bell at New York Stock Exchange 3
... Market to Demonstrate Test,s Potential for ... Rapid ... DIAG) and Applied Biosystems Inc. (NYSE: ABI ) today,announced the launch ... searches for a unique gene expression signature,identified by DiaGenic using a custom ...
... Have Other Important Benefits, Says CRN-, WASHINGTON, ... Study II, to be released at the American ... the November 12,issue of the Journal of the ... vitamin E and C supplementation on cardiovascular,events in ...
Cached Medicine Technology:Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 2Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 3Physicians' Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease 4
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The New ... and lyrical music, will be performed by the award-winning ... Estates, CA, this March 6-22, 2015, on Fridays, Saturdays ... at Peninsula High School (27118 Silver Spur Road, ... hour before the program or may be purchased on-line ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , BATESVILLE, Ind., and ANDOVER, Mass., Sept. ... strategic partnership agreement to integrate the Radianse real-time location system ... this move, Hill-Rom intends to extend its leadership in health ... obstacles for health care customers as they consider high-precision, enterprise-wide ...
... ... Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints ... Caregiver from October 26-27, 2009 in New Orleans, LA. , ... Horsham, PA (Vocus) September 2, 2009 ...
... Sept. 2 The following is an updated GlaxoSmithKline Consumer Healthcare statement ... orlistat: , , On August 24th the FDA ... serious adverse events. , , To view the Multimedia ... It,s important consumers know that alli is safe and effective ...
... , , , ... Sept. 2 /PRNewswire-FirstCall/ -- ... that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other ... Doman, President and Chief Executive Officer, will present a corporate overview ...
... on their calls , TUESDAY, Sept. 1 (HealthDay ... research suggests they can appreciate music inspired by the ... similar to soothing monkey calls, the animals moved less ... distress calls, they became anxious. , This may not ...
... N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ANPG), ... joined the Board of Directors. , , Dr. ... care, specifically with HIV treatment and immunology. Currently he is ... Academy of HIV Medicine. In 2000, he founded his current ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Scientists Make Sweet Monkey Music 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3
... HeartMate II Left Ventricular Assist System (LVAS) ... shown to restore hemodynamic function and improve ... the rotary action of a single-moving part, ... full circulatory support by pumping blood from ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
Medicine Products: